These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23327866)

  • 21. Tumor-associated Macrophages Mediate Gefitinib Resistance in Lung Cancer through HGF/c-met Signaling Pathway.
    Tang X; Chen Y; Jiao D; Liu X; Chen J; Liu Y; Jiang C; Chen Q
    Anticancer Agents Med Chem; 2024; 24(1):30-38. PubMed ID: 37957870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
    Feng W; Xie Q; Liu S; Ji Y; Li C; Wang C; Jin L
    Cancer Sci; 2018 Jun; 109(6):1775-1786. PubMed ID: 29624806
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
    Chen B; Zheng J; Zeng Y; Li B; Xie B; Zheng J; Zhou J; Zhang W
    PLoS One; 2014; 9(12):e114074. PubMed ID: 25474307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion].
    Kang XH; Wang LF; Cao F; Fan FT; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
    Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
    J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
    Zhou YM; Liu J; Sun W
    Asian Pac J Cancer Prev; 2014; 15(3):1391-6. PubMed ID: 24606471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
    Cui SX; Zhang YS; Chu JH; Song ZY; Qu XJ
    Cell Physiol Biochem; 2015; 35(1):201-12. PubMed ID: 25591763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
    Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
    Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
    Sakai A; Kasahara K; Ohmori T; Kimura H; Sone T; Fujimura M; Nakao S
    J Thorac Oncol; 2012 Sep; 7(9):1337-44. PubMed ID: 22722827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
    Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
    Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.
    Oh HN; Lee MH; Kim E; Kwak AW; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32070026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells.
    Oh HN; Kwak AW; Lee MH; Kim E; Yoon G; Cho SS; Liu K; Chae JI; Shim JH
    Phytomedicine; 2021 Jan; 80():153355. PubMed ID: 33039730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
    Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
    Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
    Xu H; Stabile LP; Gubish CT; Gooding WE; Grandis JR; Siegfried JM
    Clin Cancer Res; 2011 Jul; 17(13):4425-38. PubMed ID: 21622718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.
    Ahn SY; Kim J; Kim MA; Choi J; Kim WH
    Anticancer Res; 2017 Mar; 37(3):1127-1138. PubMed ID: 28314274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
    Han SY; Ding HR; Zhao W; Teng F; Li PP
    BMC Complement Altern Med; 2014 May; 14():165. PubMed ID: 24884778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.